A Phase 1B Study of the Anti-PD-1 Monoclonal Antibody, Tislelizumab, in Combination with the Parp Inhibitor, Pamiparib, in Advanced Solid Tumors

Michael Friedlander, T. Meniawy, B. Markman, L. R. Mileshkin, Paul Harnett, M. Millward, J. Lundy, A. E. Freimund, C. Norris, J. Wu, V. Paton, L. Wang, B. Gao

Research output: Contribution to journalAbstract/Meeting Abstract

Original languageEnglish
Pages (from-to)58-59
Number of pages2
JournalAsia-Pacific Journal of Clinical Oncology
Volume14
Publication statusPublished - Aug 2018
Externally publishedYes

Cite this

Friedlander, Michael ; Meniawy, T. ; Markman, B. ; Mileshkin, L. R. ; Harnett, Paul ; Millward, M. ; Lundy, J. ; Freimund, A. E. ; Norris, C. ; Wu, J. ; Paton, V. ; Wang, L. ; Gao, B. / A Phase 1B Study of the Anti-PD-1 Monoclonal Antibody, Tislelizumab, in Combination with the Parp Inhibitor, Pamiparib, in Advanced Solid Tumors. In: Asia-Pacific Journal of Clinical Oncology. 2018 ; Vol. 14. pp. 58-59.
@article{526ba1bf5f504e59921d1e5f0f31886e,
title = "A Phase 1B Study of the Anti-PD-1 Monoclonal Antibody, Tislelizumab, in Combination with the Parp Inhibitor, Pamiparib, in Advanced Solid Tumors",
author = "Michael Friedlander and T. Meniawy and B. Markman and Mileshkin, {L. R.} and Paul Harnett and M. Millward and J. Lundy and Freimund, {A. E.} and C. Norris and J. Wu and V. Paton and L. Wang and B. Gao",
year = "2018",
month = "8",
language = "English",
volume = "14",
pages = "58--59",
journal = "Asia–Pacific Journal of Clinical Oncology",
issn = "1743-7555",
publisher = "John Wiley & Sons",

}

Friedlander, M, Meniawy, T, Markman, B, Mileshkin, LR, Harnett, P, Millward, M, Lundy, J, Freimund, AE, Norris, C, Wu, J, Paton, V, Wang, L & Gao, B 2018, 'A Phase 1B Study of the Anti-PD-1 Monoclonal Antibody, Tislelizumab, in Combination with the Parp Inhibitor, Pamiparib, in Advanced Solid Tumors' Asia-Pacific Journal of Clinical Oncology, vol. 14, pp. 58-59.

A Phase 1B Study of the Anti-PD-1 Monoclonal Antibody, Tislelizumab, in Combination with the Parp Inhibitor, Pamiparib, in Advanced Solid Tumors. / Friedlander, Michael; Meniawy, T.; Markman, B.; Mileshkin, L. R.; Harnett, Paul; Millward, M.; Lundy, J.; Freimund, A. E.; Norris, C.; Wu, J.; Paton, V.; Wang, L.; Gao, B.

In: Asia-Pacific Journal of Clinical Oncology, Vol. 14, 08.2018, p. 58-59.

Research output: Contribution to journalAbstract/Meeting Abstract

TY - JOUR

T1 - A Phase 1B Study of the Anti-PD-1 Monoclonal Antibody, Tislelizumab, in Combination with the Parp Inhibitor, Pamiparib, in Advanced Solid Tumors

AU - Friedlander, Michael

AU - Meniawy, T.

AU - Markman, B.

AU - Mileshkin, L. R.

AU - Harnett, Paul

AU - Millward, M.

AU - Lundy, J.

AU - Freimund, A. E.

AU - Norris, C.

AU - Wu, J.

AU - Paton, V.

AU - Wang, L.

AU - Gao, B.

PY - 2018/8

Y1 - 2018/8

M3 - Abstract/Meeting Abstract

VL - 14

SP - 58

EP - 59

JO - Asia–Pacific Journal of Clinical Oncology

JF - Asia–Pacific Journal of Clinical Oncology

SN - 1743-7555

ER -